15/09/2015 07:13:07

CORRECTION: CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

This is a correction of the announcement from 17:45 14.09.2015 CEST. Reason for the correction: In "About Sayre Therapeutics", one should have read that Shukrit and Vandana are co-founders at Sayre Therapeutics and not at Biocon. This version replaces and cancels the previous one.

CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

Chenôve (France) and Bangalore (India), September 14 2015 - CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) , the creator of ZENEO®, a needle-free injection system developed to be used with a portfolio of well-known drugs announces today a partnering agreement with Sayre Therapeutics to commercialise ZENEO® Methotrexate in India. The filing of the marketing authorisation files of this innovative product for the treatment of rheumatoid arthritis in the region, is anticipated early 2017.


The agreement provides Sayre Therapeutics with exclusive distribution and marketing rights  in India, Bangladesh, Sri Lanka and Nepal. In return, CROSSJECT will receive a share from 20% to 40% of the revenues generated from the product. Sayre Therapeutics has committed to minimum levels of volumes and marketing investment.


Patrick Alexandre, CROSSJECT's founder and CEO said: "The Indian market has been chosen due to the pricing environment which will allow us to generate attractive returns. This is a high margin niche market thanks to the free pricing mechanisms in this area. This deal will allow us to capture value from ZENEO® without any further investments. It also allows us to continue to focus our  commercial strategy on North America and Europe. We are convinced that Sayre Therapeutics with its entrepreneurial spirit, experienced team, including its sales force, has all the attributes needed to successfully  commercialise ZENEO® Methotrexate."

A spokesperson for Sayre Therapeutics comments: "This collaboration with CROSSJECT will further reinforce our product portfolio, particularly for the home care market. Sayre Therapeutics is now well established  through the Indian subcontinent and South Asia, and we are now ready to focus on chronic diseases  such as  rheumatoid arthritis by providing patients with a needle-free injection system that is easy and safe to use."


About Crossject  ·  www.crossject.com

Crossject is using its world-leading needle-free injection system, ZENEO(TM) to develop an attractive pipeline of high-value SUPERGENERICS or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.

Crossject's needle-free, pre-filled, single-use ZENEO (TM) injection systems are unique in that they can be tailored to deliver drugs intradermally, subcutaneously and intramuscularly. This means that ZENEO(TM) can allow a wide range of drugs and vaccines for a broad range of indications to be developed and approved in a very short period. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

CROSSJECT is listed on Alternext Paris (Mnemo : ALCJ, ISIN : FR0011716265)


About Sayre Therapeutics

Sayre Therapeutics is specialized in innovative treatments and medical devices commercialization in South Asia. The founders experience and its dynamic team have allowed Sayre to rapidly develop its product portfolio.

 Follow us on Twitter @Crossject




Patrick Alexandre / Timothée Muller


Citigate Dewe Rogerson

Laurence Bault /Lucie Larguier

+33 (0)1 53 32 84 78 / 84 75




PDF version

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: CROSSJECT via Globenewswire


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Sep
Goodwrench, sikke en omgang vrøvl.   Det er ikke kun hyklerisk, men også dybt patetisk, når du komme..
21 Sep
Nogle gange...bare nogle gange ville jeg godt nok vaere glad og taknemmelig hvis vi ikke evig og alt..
19 Sep
Her er min model ;)      
21 Sep
Hej   Der er lige nu kommet nye tal fra Conference Board omkring de ledende indikatorer. Vores konju..
24 Sep
De fleste danskere, svenskere og tyskere er ikke racister. Men at se sit land blive invaderet af mus..
20 Sep
Norwegian har gjort det flot, og konkurrence kan være godt det "kan" højne kvaliteten i nogen tilfæl..
18 Sep
Goodwrench, har du da hørt en loppe gø. Det er dybt imponerende, hvordan du igen og igen udstiller d..
20 Sep
Donlupo - Fik du skrevet fra den forkerte profil?
23 Sep
Kun 3,4 på Richerskalaen. Det er nok bare Fedekim, der har vendt sig i sengen.
23 Sep
Jeg har nedskrevet min strategi efter, at jeg er blevet træt af dumme indkøb med for magt EI skramme..

Form 8.5 (EPT/RI) - Booker Group plc

25/09/2017 08:07:28
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Alliance Trust PLC : Transaction in Own Shares

25/09/2017 07:39:49
25 September 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 22 September 2017 the Company purchased for cancellation 54,330 ordinary shares of 2.5p each at a price of 704.6964p per share.  Therefore, the total number of voting rights in the Company is now 349,635,321.    The above figure (349,635,321) may be used by sh..

Novae Group plc: Holdings in Company

22/09/2017 15:30:32
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Gigya, the Market Leader in Customer Identity and Access Management, to be Acquired by SAP
iLOOKABOUT Launches New Mobile Appraiser Product at IAAO Conference
Aerojet Rocketdyne Supports ULA Launch of Classified Satellite for the U.S. Government
OCEANTEAM ASA - Dutch Jos van Dijk appointed Group Chief Financial Officer (CFO)
Thinfilm Launches NFC Scanner App for iPhones as Apple Extends NFC Functionality Beyond Payments with Release of iOS 11

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
25 September 2017 14:13:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170921.1 - EUROWEB3 - 2017-09-25 15:13:04 - 2017-09-25 14:13:04 - 1000 - Website: OKAY